Area of research
Obstetrics and Gynecology · Reproductive Medicine
Research interest
Research interests include Endometrial and Cervical Cancer Treatments, Ovarian cancer diagnosis and treatment, Uterine Myomas and Treatments, and Minimally Invasive Surgical Techniques.
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study
Updates and controversies in the management of uterine serous carcinoma and uterine carcinosarcoma
LOW NEUTROPHIL-TO-LYMPHOCYTE RATIO IS ASSOCIATED WITH IMPROVED PROGRESSION FREE SURVIVAL IN PATIENTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER: AN ANCILLARY ANALYSIS OF NRG-GY018
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Low-grade serous ovarian cancer: expert consensus report on the state of the science
Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis
NCCN Guidelines Insights: Cervical Cancer, Version 1.2020
Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis
Enhanced Recovery and Surgical Optimization Protocol for Minimally Invasive Gynecologic Surgery: An AAGL White Paper
Low-grade serous ovarian cancer: State of the science
Understanding the “Scope” of the Problem: Why Laparoscopy Is Considered Safe during the COVID-19 Pandemic
When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic
Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis
Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, part I
Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, Part II
Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer
PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function
Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers
Minimally invasive hysterectomy surgery rates for endometrial cancer performed at National Comprehensive Cancer Network (NCCN) Centers
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation
Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis
Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Patient, surgeon, and hospital disparities associated with benign hysterectomy approach and perioperative complications
Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis
Cervical Cancer, Version 2.2015